Αρχική World News Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with AML...

Whole-Genome Sequencing Provides Rapid and Accurate Genomic Profiling in Patients with AML or MDS

The researchers from the Washington University School of Medicine in St. Louis, MO, US reported on 11 March 2021 issue of The New England Journal of Medicine findings from the genomic profiling performed in 263 patients with acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS). The study results show that whole-genome sequencing is equivalent to or better than conventional cytogenetic analysis, both in analytical performance and clinical applicability. Whole-genome sequencing provided a greater diagnostic yield and more efficient risk stratification on the basis of standard risk categories according to Dr. David H. Spencer and colleagues.

Conventional cytogenetic analysis is currently an essential component of the diagnostic work-up for patients with AML or MDS. The authors wrote in background that advances in sequencing have improved the ability to identify genetic mutations, but the detection of chromosomal rearrangements is primarily performed through conventional cytogenetic analysis, e.g. karyotyping, which is effective, but has several limitations, including the need to obtain viable cells, low sensitivity, and limited resolution. Fluorescence in situ hybridisation (FISH) and targeted sequencing assays that use DNA, RNA, or both are also used, but these methods are informative only in the regions selected for analysis and may provide incomplete information regarding identified chromosomal rearrangements.

Variety of clinically relevant mutations suggest that whole-genome sequencing could be used instead standard testing. However, its accuracy, feasibility, and clinical utility have not been demonstrated. In this study, the researchers applied whole-genome sequencing for genomic profiling of patients with AML or MDS in real time to evaluate its feasibility, accuracy, and clinical utility.

The study team detected mutations for risk stratification by using European Leukemia Network guidelines. They analyzed the performance of whole-genome sequencing by comparing the results with findings from cytogenetic analysis and targeted sequencing. From 263 patients with myeloid cancers, 235 had undergone successful cytogenetic analysis.

Whole-genome sequencing detected all 40 recurrent translocations and 91 copy-number alterations that had been identified by cytogenetic analysis. In addition, it identified new clinically relevant genomic events in 40 of 235 patients (17.0%).

Prospective sequencing of samples obtained from 117 consecutive patients was performed in a median of 5 days and provided new genetic information in 29 patients (24.8%), which changed the risk category for 19 patients (16.2%).

Standard AML risk groups, as defined by sequencing results instead of cytogenetic analysis, correlated with clinical outcomes. Whole-genome sequencing was also used to stratify patients who had inconclusive results by cytogenetic analysis into risk groups in which clinical outcomes were measurably different.

The authors concluded that whole-genome sequencing detected 100% of the clinically significant abnormalities that had been identified by cytogenetic analysis and clinical FISH assays. In addition, sequencing provided new genetic information in almost 25% of patients, more than half of whom would have been assigned to a different genetic risk category with results from conventional testing. 

Prospective real-time sequencing of samples yielded complete genomic information in a clinically relevant timeframe. Although larger studies are needed to firmly establish the clinical performance of whole-genome sequencing, this proof-of-concept study showed that this method has the potential to add prognostic value by expanding risk stratification to more patients, especially for those with inconclusive results on cytogenetic analysis and where whole-genome sequencing could have an immediate effect on treatment decisions.

The study was funded by the Siteman Cancer Research Fund and others.

Reference

Duncavage EJ, Schroeder MC, O’Laughlin M, et al. Genome Sequencing as an Alternative to Cytogenetic Analysis in Myeloid Cancers. N Engl J Med 2021;384:924-935. DOI: 10.1056/NEJMoa2024534.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer

On 13 October 2021, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) in combination with chemotherapy, with or without bevacizumab, for...

From Scan to Scan: The Challenges of Living with Metastatic Cancer

October 15, 2021, by NCI Staff Bethany Ross has been living with metastatic neuroendocrine cancer since she was diagnosed in 2018. Credit: Used with permission from...

The award-winning researcher behind next generation sequencing

Next generation sequencing (NGS) has given the genomic research community ultra-high throughput, scalability, and speed that could only be dreamed of 20 years ago....

Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t Tell Their Doctors

Cancer and cancer treatment come with many side effects, including nausea, vomiting, and pain. In addition to the physical toll, the impacts to a...

Medicare Open Enrollment Starts Tomorrow!

Medicare open enrollment is upon us for 2022. If you are a Medicare recipient, this is the time of year when you can make...

Cancer in My Community: Providing Supportive Care in Serbia

Cancer in My Community is a Cancer.Net Blog series that shows the global impact of cancer and how people work to care for those with...